The GLP-1 receptor agonist liraglutide used to treat patients with type 2 diabetes (T2D) for 26 weeks had no impact on bone resorption, even though subjects lost weight.
The U.S. Food and Drug Administration has approved an omega-3 fatty acid treatment as an add-on treatment to statin therapy to reduce the risk of cardiovascular disease in adults with elevated triglyceride levels.
In this slideshow, we review 10 new drugs or new indications for diabetes and other endocrine conditions.
A 58-year-old man with a history of diabetes mellitus type 1 went to the urgent care after he awoke one morning and noticed the bottom of his foot near his toes felt funny. When he looked at the area, he realized that a bulla had formed on the bottom of his foot overnight. He hadn’t injured or cut the foot or leg recently, and he felt in good health otherwise. What's your diagnosis?
Researchers writing in the New England Journal of Medicine report that a combination treatment of ticagrelor and aspirin leads to improved cardiovascular disease outcomes in patients with stable coronary artery disease and diabetes mellitus.
The type 2 diabetes drug dapagliflozin reduces the risk for worsening heart failure or death from cardiovascular disease among individuals with heart failure and reduced ejection fraction, whether or not they have diabetes, shows a study published in the New England Journal of Medicine.
Adults with early type two diabetes and elevated cardiovascular risk may be able to safely take linagliptin or sulfonylurea (glimepiride) without increasing their risk of cardiovascular events, researchers report in JAMA.
Among adults with recently-diagnosed type 2 diabetes and elevated cardiovascular risk, the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin and the sulfonylurea glimepiride treatment resulted in similar cardiovascular outcomes over a median 6.3 years.
Men with diabetes may have a higher risk of experiencing chronic lower back pain, say researchers writing in BMJ Open this month.
US adults with diagnosed diabetes are no closer to treatment goals than they were in 2005, according to a new study.